US-based pharmaceutical company Eli Lilly to invest more than $1 billion in India over the coming years. The investment aims to boost manufacturing and supply capacity through strategic collaborations with local drugmakers. By leveraging India’s skilled workforce, Lilly seeks to strengthen its global manufacturing network and enhance the availability of its key medicines worldwide.
Entry into India’s Pharmaceutical Manufacturing Sector
Earlier this year, Lilly introduced its weight-loss drug, Mounjaro, in India. While the company currently does not operate its own manufacturing facility in the country, India serves as a hub for several companies that develop and produce complex drugs, vials, and injectables on a contract basis for global pharmaceutical firms. Through these partnerships, Lilly aims to expand production capabilities and ensure the steady supply of its medicines.
Focus on Key Therapeutic Areas
The collaborations will target critical therapeutic areas, including obesity, diabetes, Alzheimer’s, cancer, and autoimmune conditions. The goal is to increase patient access to Lilly’s medicines while strengthening the company’s global manufacturing resilience.
“We are making significant investments to increase manufacturing and medicine supply capacity around the world,” said Patrik Jonsson, President of Lilly International, adding that India is a hub for capability building within our global network.
Global Trends and Regulatory Drivers
Pharmaceutical companies are pushing globally to expand manufacturing in the United States, and Lilly invests in India amid this trend, partly driven by the Trump administration’s 100% tariff on imported branded and patented drugs, effective October 1, 2025.
Rising Demand for Obesity Treatments in India
The launch of Mounjaro, alongside Danish drugmaker Novo Nordisk’s Wegovy, has heightened awareness of obesity treatments in India. With projections indicating that India will have the world’s second-largest obese population by 2050, the market for such therapies is poised for substantial growth.
Strengthening India’s Role in Global Pharma
As reported by msn.com, through these investments and partnerships, Eli Lilly is positioning India as a critical hub in its global supply chain, reinforcing the country’s role in the production of innovative medicines while supporting Lilly’s long-term growth strategy in key therapeutic areas.
